Securities class actions against life sciences companies are generally second-order problems. The first-order problem is a business or regulatory setback that, when disclosed by the company or a third party, is followed by a stock price drop. Following the decline, plaintiffs’ class action attorneys search the company’s previous public statements for inconsistencies between past positive comments and the current negative development. In most cases, plaintiffs’ attorneys then seek to show that any arguable inconsistency amounts to fraud—that is, they will claim that the earlier statement was knowingly or recklessly false or misleading. When a company makes the challenged statement in a public offering document (that is, a registration statement or prospectus), plaintiffs need to show that the statement was materially false or misleading, but not that it was made with scienter, i.e., the requisite state of mind.
https://ma-litigation.sidley.com/wp-content/uploads/sites/3/2022/08/sidleyLogo-e1643922598198.png00Robin E. Wechkinhttps://ma-litigation.sidley.com/wp-content/uploads/sites/3/2022/08/sidleyLogo-e1643922598198.pngRobin E. Wechkin2023-05-17 09:30:042023-09-08 10:15:06Securities Litigation Against Life Sciences Companies: Eleven Takeaways from 2022
The boardroom frequently presents attorney-client privilege and work product protection issues. The Delaware Court of Chancery’s recent decision in Hyde Park Venture Partners Fund III, LP v. FairXchange, LLC, C.A. No. 2022-0344-JTL (Del. Ch. March 9, 2023), provides a reminder of the importance of vigilance in considering when and how to limit a director’s access to privileged materials in circumstances where directors’ interests may diverge – particularly where directors manage, or are affiliated with, investment funds owning stock of the Company.
https://ma-litigation.sidley.com/wp-content/uploads/sites/3/2022/08/sidleyLogo-e1643922598198.png00Hille R. Sheppardhttps://ma-litigation.sidley.com/wp-content/uploads/sites/3/2022/08/sidleyLogo-e1643922598198.pngHille R. Sheppard2023-05-16 09:23:552023-09-08 10:16:03Good Fences Make Good Neighbors and Preserve Attorney-Client Privilege in the Boardroom: A Word of Caution for Boards Navigating Potential Disputes Among Directors or With Funds They Manage
This blog frequently has covered SPAC-related litigation (recently, here, here, and here), and the potential consequences of the Delaware Court of Chancery’s rulings in the MultiPlan and Gig3 cases. As discussed previously, the decisions in Multiplan and Gig3, among others, may portend increased litigation surrounding de-SPAC transactions, and particular focus by the plaintiffs’ bar on any actual or perceived conflicts of interest. A relatively recent complaint filed in the Court of Chancery targeting the Lottery.com SPAC deal may represent plaintiffs’ attorneys further widening the net of liability: the case targets not only the SPAC fiduciaries themselves but also the independent financial advisor that purportedly conducted due diligence in connection with the de-SPAC transaction. Financial advisors often are intimately involved in the SPAC process: they help screen which companies are attractive targets for a SPAC merger and, once a target is chosen, conduct diligence to determine that the target is a genuinely good merger partner. The Lottery.com complaint focuses on the financial advisors’ due diligence and on an allegedly conflict-prone compensation structure for those advisors, and alleges liability against an additional (and often deep-pocketed) class of defendant.
Securities Litigation Against Life Sciences Companies: Eleven Takeaways from 2022
Securities class actions against life sciences companies are generally second-order problems. The first-order problem is a business or regulatory setback that, when disclosed by the company or a third party, is followed by a stock price drop. Following the decline, plaintiffs’ class action attorneys search the company’s previous public statements for inconsistencies between past positive comments and the current negative development. In most cases, plaintiffs’ attorneys then seek to show that any arguable inconsistency amounts to fraud—that is, they will claim that the earlier statement was knowingly or recklessly false or misleading. When a company makes the challenged statement in a public offering document (that is, a registration statement or prospectus), plaintiffs need to show that the statement was materially false or misleading, but not that it was made with scienter, i.e., the requisite state of mind.
(more…)
Robin E. Wechkin
Seattle
rwechkin@sidley.com
Sarah A. Hemmendinger
San Francisco
shemmendinger@sidley.com
Sara B. Brody
San Francisco, Palo Alto
sbrody@sidley.com
Matthew J. Dolan
Palo Alto
mdolan@sidley.com
Francesca E. Brody
New York
fbrody@sidley.com
Good Fences Make Good Neighbors and Preserve Attorney-Client Privilege in the Boardroom: A Word of Caution for Boards Navigating Potential Disputes Among Directors or With Funds They Manage
The boardroom frequently presents attorney-client privilege and work product protection issues. The Delaware Court of Chancery’s recent decision in Hyde Park Venture Partners Fund III, LP v. FairXchange, LLC, C.A. No. 2022-0344-JTL (Del. Ch. March 9, 2023), provides a reminder of the importance of vigilance in considering when and how to limit a director’s access to privileged materials in circumstances where directors’ interests may diverge – particularly where directors manage, or are affiliated with, investment funds owning stock of the Company.
(more…)
Hille R. Sheppard
Chicago
hsheppard@sidley.com
Kai H.E. Liekefett
New York
kliekefett@sidley.com
Ross O. Kloeber IV
Plaintiffs Try Their Luck Against Lottery.com SPAC Financial Advisor
This blog frequently has covered SPAC-related litigation (recently, here, here, and here), and the potential consequences of the Delaware Court of Chancery’s rulings in the MultiPlan and Gig3 cases. As discussed previously, the decisions in Multiplan and Gig3, among others, may portend increased litigation surrounding de-SPAC transactions, and particular focus by the plaintiffs’ bar on any actual or perceived conflicts of interest. A relatively recent complaint filed in the Court of Chancery targeting the Lottery.com SPAC deal may represent plaintiffs’ attorneys further widening the net of liability: the case targets not only the SPAC fiduciaries themselves but also the independent financial advisor that purportedly conducted due diligence in connection with the de-SPAC transaction. Financial advisors often are intimately involved in the SPAC process: they help screen which companies are attractive targets for a SPAC merger and, once a target is chosen, conduct diligence to determine that the target is a genuinely good merger partner. The Lottery.com complaint focuses on the financial advisors’ due diligence and on an allegedly conflict-prone compensation structure for those advisors, and alleges liability against an additional (and often deep-pocketed) class of defendant.
(more…)
James Heyworth
New York
jheyworth@sidley.com
Martin W. Sigalow
New York
msigalow@sidley.com
Categories
Archives
Meet the Team
Charlotte K. Newell
cnewell@sidley.com
Jaime A. Bartlett
jbartlett@sidley.com
Elizabeth Y. Austin
laustin@sidley.com
Adam Cromie
adam.cromie@sidley.com
Matthew J. Dolan
mdolan@sidley.com
Jim Ducayet
jducayet@sidley.com
Yolanda C. Garcia
ygarcia@sidley.com
James Heyworth
jheyworth@sidley.com
Alex J. Kaplan
ajkaplan@sidley.com
Peter J. Mardian
pmardian@sidley.com
Jon Muenz
jmuenz@sidley.com
Ian M. Ross
iross@sidley.com
Hille R. Sheppard
hsheppard@sidley.com
Heather Benzmiller Sultanian
hsultanian@sidley.com
Robert S. Velevis
rvelevis@sidley.com
Robin E. Wechkin
rwechkin@sidley.com
Caroline A. Wong
caroline.wong@sidley.com